Monia Brett P

Monia Brett P, chief executive officer of Ionis Pharmaceuticals (IONS), has been a consistent seller of company stock over the past year, with Form 4 filings showing 61 total transactions across two companies. The overwhelming majority of activity centers on IONS, where open-market sales totaled roughly $48.5 million against zero open-market purchases. The selling has been steady and substantial: a single day on March 9, 2026, saw three separate sales worth approximately $10.5 million combined, while a January 30, 2026, sale brought in $5.2 million. The most recent cluster, from June 24–26, 2026, shows three sales totaling about $6.8 million, each paired with option exercises of similar magnitude—a pattern indicating the shares sold were largely acquired through exercised options rather than newly purchased stock. The transaction mix reveals a compensation-driven disposition strategy rather than a concentrated dumping of existing holdings. Every sale in the recent window is matched by an "M" code (option exercise) of slightly lower value, meaning Monia is exercising options and immediately selling a portion of the resulting shares. The only non-IONS activity is a zero-value grant of shares in Cogent Biosciences (CGTX) on June 17, 2026, which carries no cash consideration. Across all filings, the total acquired value—including grants and option exercises—is just under $60,000, a fraction of the $48.5 million sold. The direction is unambiguous: a persistent, high-volume sell bias in IONS, with no open-market purchases recorded at any point in the filing history.